Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 44.25 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 43.10 | Oscillator | Neutral |
| Williams %R (14) | -74.73 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.17 (Hist -0.10) | Oscillator | Strong Sell |
| Average Directional Index (14) | 12.43 (+DI 15.6 / -DI 22.4) | Trend | Neutral |
| EMA 20 | 28.95 | MA | Strong Sell |
| SMA 20 | 29.11 | MA | Strong Sell |
| EMA 50 | 29.24 | MA | Strong Sell |
| SMA 50 | 29.14 | MA | Strong Sell |
| SMA 200 | 27.13 | MA | Buy |
Current price $27.71
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 24, 26 | Truist Securities | maintain | Hold | Hold |
| Aug 21, 26 | Barclays | maintain | Overweight | Overweight |
| Aug 11, 26 | Needham | maintain | Buy | Buy |
| Aug 11, 26 | Citigroup | maintain | Neutral | Neutral |
| Aug 11, 26 | Deutsche Bank | maintain | Hold | Hold |
| Aug 11, 26 | TD Cowen | maintain | Hold | Hold |
| Aug 11, 26 | B of A Securities | maintain | Neutral | Neutral |
| Aug 11, 26 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Jul 24, 26 | Truist Securities | maintain | Hold | Hold |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 14, 26 | Boughton Soleil | officer: Chief Legal Officer | S-Sale | 3,461 @ $29.06 | $100.6K |
| Oct 9, 26 | Franklin Jonathan M | officer | 0 | — | |
| Oct 1, 26 | Okupe Oluyemi | officer: Chief Financial Officer | S-Sale | 2,000 @ $29.70 | $59.40K |
| Sep 30, 26 | Boughton Soleil | officer: Chief Legal Officer | S-Sale | 3,461 @ $29.17 | $101.0K |
| Sep 22, 26 | Okupe Oluyemi | officer: Chief Financial Officer | M-Exempt | 14,000 @ $5.01 | $70.14K |
| Sep 22, 26 | Okupe Oluyemi | officer: Chief Financial Officer | S-Sale | 29,277 @ $29.95 | $876.8K |
| Sep 22, 26 | Okupe Oluyemi | officer: Chief Financial Officer | M-Exempt | 14,000 @ $5.01 | $70.14K |
| Sep 17, 26 | Okupe Oluyemi | officer: Chief Financial Officer | S-Sale | 12,313 @ $28.82 | $354.9K |
Stock news · updated daily
Hims and Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewi
NEW YORK and NEW ORLEANS, Oct. 23, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS), if they purchased or otherwise acquired the Company's securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period").
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $27.71, marking a -4.87% move from the previous day.
San Diego, California--(Newsfile Corp. - October 23, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). Hims operates a health and wellness platform that connects consumers to licensed healthcare professionals.
Hims & Hers Health Inc. (NYSE:HIMS) urged a court to throw out a consumer deception lawsuit, asserting that plaintiffs ignored clear, upfront disclosures regarding data privacy, subscription charges, and cancellation policies.
New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline. SO WHAT: If you purchased Hims securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious business misconduct. Hagens Berman, which is actively investigating the alleged claims, encourages HIMS investors who suffered substantial losses to submit your losses now.
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 10, 2026 | -0.05 | -0.37 | Miss -643.1% | $753.2M |
| May 11, 2026 | 0.03 | -0.40 | Miss -1676.7% | $608.1M |
| Feb 23, 2026 | 0.02 | 0.07 | Beat 250.0% | $617.8M |
| Nov 3, 2025 | 0.09 | 0.06 | Miss -33.3% | $599.0M |
| Aug 4, 2025 | 0.18 | 0.17 | Miss -5.6% | $544.8M |
| May 5, 2025 | 0.12 | 0.20 | Beat 65.4% | $586.0M |
TTM vs. 5-year historical average (annual ratios)
| Metric | HIMS | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -45.4x | -2.7x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -47.0x | EPS est. -0.59 | In line |
| Price / Book | 19.8x | 7.5x | Elevated |
| Price / Sales | 2.4x | 3.2x | Discount |
| EV / EBITDA | -93.8x | -15.5x | Elevated |
| Return on equity | -30.0% | — | Weak |
| Gross margin | 64.7% | 77.6% | Below hist. |
| Debt / Equity | 4.77 | 0.43 | Levered |
| Piotroski / Altman Z | 2/9 | Z 1.56 | Distress |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 15, 2026 | 2026-10-15 16:44:57 | View |
| 3 | Oct 15, 2026 | 2026-10-15 16:44:51 | View |
| 8-K | Oct 7, 2026 | 2026-10-07 16:13:26 | View |
| 4 | Oct 2, 2026 | 2026-10-02 16:32:05 | View |
| 4 | Oct 2, 2026 | 2026-10-02 16:31:59 | View |
| 4 | Sep 23, 2026 | 2026-09-23 16:17:12 | View |
| 4 | Sep 18, 2026 | 2026-09-18 16:17:22 | View |
| 4 | Sep 17, 2026 | 2026-09-17 16:17:25 | View |
| 4 | Sep 17, 2026 | 2026-09-17 16:17:21 | View |
| 4 | Sep 17, 2026 | 2026-09-17 16:17:16 | View |
Proxy statement (DEF 14A) disclosures
FY2025 · 10-K disclosure